» Articles » PMID: 19008265

Effect of Fibre, Antispasmodics, and Peppermint Oil in the Treatment of Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Overview
Journal BMJ
Specialty General Medicine
Date 2008 Nov 15
PMID 19008265
Citations 148
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.

Design: Systematic review and meta-analysis of randomised controlled trials.

Data Sources: Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting.

Results: 12 studies compared fibre with placebo or no treatment in 591 patients (relative risk of persistent symptoms 0.87, 95% confidence interval 0.76 to 1.00). This effect was limited to ispaghula (0.78, 0.63 to 0.96). Twenty two trials compared antispasmodics with placebo in 1778 patients (0.68, 0.57 to 0.81). Various antispasmodics were studied, but otilonium (four trials, 435 patients, relative risk of persistent symptoms 0.55, 0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63, 0.51 to 0.78) showed consistent evidence of efficacy. Four trials compared peppermint oil with placebo in 392 patients (0.43, 0.32 to 0.59).

Conclusion: Fibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome.

Citing Articles

Low-FODMAP Diet for Irritable Bowel Syndrome: Insights from Microbiome.

Zhang H, Su Q Nutrients. 2025; 17(3).

PMID: 39940404 PMC: 11819959. DOI: 10.3390/nu17030544.


Neurogastroenterology and motility disorders in patients with cirrhosis.

Idalsoaga F, Ayares G, Blaney H, Cabrera D, Chahuan J, Monrroy H Hepatol Commun. 2025; 9(1.

PMID: 39773873 PMC: 11717532. DOI: 10.1097/HC9.0000000000000622.


Impact of HADS Anxiety and Depression Scores on the Efficacy of Dietary Interventions for Irritable Bowel Syndrome.

OConnor A, Gill S, Neary E, White S, Ford A Aliment Pharmacol Ther. 2024; 61(1):177-185.

PMID: 39392338 PMC: 11636188. DOI: 10.1111/apt.18337.


Functional Bowel Disorder Management in Routine Practice with Tips for Hot Topics: Expert Opinion Review.

Akyuz F, Celebi A, Dogan I, Erzin Y, Kav T, Soyturk M Turk J Gastroenterol. 2024; 35(6):423-439.

PMID: 39128123 PMC: 11232060. DOI: 10.5152/tjg.2024.24029.


Update in diagnosis and management of irritable bowel syndrome.

Hung T, Wang C, Lee H Tzu Chi Med J. 2023; 35(4):306-311.

PMID: 38035060 PMC: 10683518. DOI: 10.4103/tcmj.tcmj_104_23.


References
1.
Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999; 354(9193):1896-900. DOI: 10.1016/s0140-6736(99)04149-5. View

2.
Quartero A, Meineche-Schmidt V, Muris J, Rubin G, de Wit N . Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2005; (2):CD003460. DOI: 10.1002/14651858.CD003460.pub2. View

3.
Hills J, Aaronson P . The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991; 101(1):55-65. DOI: 10.1016/0016-5085(91)90459-x. View

4.
Wilson S, Roberts L, Roalfe A, Bridge P, Singh S . Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004; 54(504):495-502. PMC: 1324800. View

5.
Tack J, Fried M, Houghton L, Spicak J, Fisher G . Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006; 24(2):183-205. DOI: 10.1111/j.1365-2036.2006.02938.x. View